Artificial antigen-presenting cells expressing CD80, CD70, and 4-1BB ligand efficiently expand functional T cells specific to tumor-associated antigens
- PMID: 24713579
- DOI: 10.1016/j.imbio.2014.03.003
Artificial antigen-presenting cells expressing CD80, CD70, and 4-1BB ligand efficiently expand functional T cells specific to tumor-associated antigens
Abstract
Professional antigen-presenting cells (APCs), notably dendritic cells (DCs), are the most potent for expanding antigen-specific T cells ex vivo. However, the labor-intensive and expensive procedure for customized preparation of autologous APCs has hampered their broad clinical application. Artificial APC (aAPC) systems, which can be readily prepared from off-the-shelf components, have been proposed as a promising alternative to custom-made professional APCs. Here, in order to develop a novel aAPC system, we established K562 erythroleukemia cells expressing different combinations of co-stimulatory molecule ligands, CD80, CD70, and/or 4-1BB ligand (4-1BBL). When nucleofected with in vitro-generated mRNA encoding a tumor-associated antigen, MART-1, the K562 cells expressing all of CD80, CD70, and 4-1BBL were the most efficient for expansion of functional T cells specific to an HLA-A2-restricted immunodominant epitope, MART-126-35. In addition, only the K562 cells expressing all three of these co-stimulatory molecule ligands could clearly expand T cells specific to other less immunogenic antigen epitopes, gp100154-162 and Cyp1B1239-247, through transfection with in vitro generated gp100 and Cyp1B1 mRNA, respectively. These results indicated that non-redundant and synergistic effects of co-stimulation via CD28/CD80, CD27/CD70, and 4-1BB/4-1BBL might be critical for eliciting efficient expansion of T cells; co-stimulation via the 4-1BB/4-1BBL interaction might expand antigen-specific T cells by preventing apoptotic cell death triggered by specific antigens in the presence of the CD28/CD80 and CD27/CD70 signaling. Taken together, our findings suggested that this K562-based aAPC system expressing CD80, CD70, and 4-1BBL would be useful for efficiently stimulating functional antigen-specific T cells ex vivo, in particular when detailed information on the epitope specificities is unavailable.
Keywords: Antigen-presenting cell; Apoptotic cell death; Co-stimulatory molecule; T cell; Tumor-associated antigen.
Copyright © 2014 Elsevier GmbH. All rights reserved.
Similar articles
-
Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells.Int Immunol. 2007 Dec;19(12):1383-94. doi: 10.1093/intimm/dxm106. Epub 2007 Oct 31. Int Immunol. 2007. PMID: 17977894
-
Preferential T cell expansion by artificial antigen presenting cells expressing 4-1BBL alone or in combination with CD80 or CD86.Iran J Immunol. 2008 Sep;5(3):136-47. Iran J Immunol. 2008. PMID: 18791280
-
Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines.J Immunother. 1998 Mar;21(2):95-108. J Immunother. 1998. PMID: 9551360
-
Role of 4-1BB:4-1BB ligand in cancer immunotherapy.Cancer Gene Ther. 2004 Mar;11(3):215-26. doi: 10.1038/sj.cgt.7700670. Cancer Gene Ther. 2004. PMID: 14671675 Review.
-
The Progress of Investigating the CD137-CD137L Axis as a Potential Target for Systemic Lupus Erythematosus.Cells. 2019 Sep 6;8(9):1044. doi: 10.3390/cells8091044. Cells. 2019. PMID: 31500130 Free PMC article. Review.
Cited by
-
Creation of an engineered APC system to explore and optimize the presentation of immunodominant peptides of major allergens.Sci Rep. 2016 Aug 19;6:31580. doi: 10.1038/srep31580. Sci Rep. 2016. PMID: 27539532 Free PMC article.
-
Primary explants of the postnatal thymus allow the expansion of clonogenic thymic epithelial cells that constitute thymospheres.Stem Cell Res Ther. 2023 Oct 31;14(1):312. doi: 10.1186/s13287-023-03529-8. Stem Cell Res Ther. 2023. PMID: 37904232 Free PMC article.
-
The ExoGAN generative AI framework enables extracellular vesicle-based immunotherapy.Res Sq [Preprint]. 2025 Jun 29:rs.3.rs-6915262. doi: 10.21203/rs.3.rs-6915262/v1. Res Sq. 2025. PMID: 40678247 Free PMC article. Preprint.
-
Advances in immunotherapy delivery from implantable and injectable biomaterials.Acta Biomater. 2019 Apr 1;88:15-31. doi: 10.1016/j.actbio.2019.02.016. Epub 2019 Feb 13. Acta Biomater. 2019. PMID: 30771535 Free PMC article. Review.
-
Transitional Insight into the RNA-Based Oligonucleotides in Cancer Treatment.Appl Biochem Biotechnol. 2024 Mar;196(3):1685-1711. doi: 10.1007/s12010-023-04597-5. Epub 2023 Jul 4. Appl Biochem Biotechnol. 2024. PMID: 37402038 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous